Literature DB >> 15310993

Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.

Eduardo I Canto1, Herb Singh, Shahrokh F Shariat, Dov Kadmon, Brian J Miles, Thomas M Wheeler, Kevin M Slawin.   

Abstract

PURPOSE: The performance characteristics of percent free (f) prostate specific antigen (PSA) for differentiating between benign prostatic hyperplasia and prostate cancer were originally established using primarily sextant biopsy. We determined whether the addition of 6 laterally directed cores to the traditional sextant prostate biopsy affects the performance of percent fPSA.
MATERIALS AND METHODS: We retrospectively evaluated a cohort of 350 consecutive biopsies in men with negative digital rectal examinations and PSA between 4 and 10 ng/ml who underwent systematic 12 core biopsy (S12C) biopsy at Scott Department of Urology between March 1999 and January 2003. The effects of 6 additional, laterally directed biopsies on the sensitivity, specificity and area under the ROC curve for percent fPSA was evaluated in the 277 men in whom percent fPSA was measured.
RESULTS: Cancers detected exclusively in the 6 laterally directed cores were associated with percent fPSA values similar to those in patients with a benign S12C biopsy. This resulted in a modest and yet predictable decrease in the sensitivity of percent fPSA at each biopsy threshold value without affecting specificity. There was a nonstatistically significant decrease in the area under the ROC curve with the addition of 6 laterally directed cores to sextant biopsy (medial sextant cores 0.66 vs S12C 0.60).
CONCLUSIONS: The 12 core biopsy strategies have a higher cancer detection rate than sextant biopsies and they are gaining widespread acceptance. The addition of 6 laterally directed cores to traditional sextant biopsy may result in a modest decrease in the sensitivity of percent fPSA at each selected biopsy threshold without affecting specificity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310993     DOI: 10.1097/01.ju.0000134619.72675.8d

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Target motion compensation in MRI-guided prostate biopsy with static images.

Authors:  Hadi Tadayyon; Andras Lasso; Sean Gill; Aradhana Kaushal; Peter Guion; Gabor Fichtinger
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2010

Review 2.  Tumor markers in prostate cancer I: blood-based markers.

Authors:  Shahrokh F Shariat; Axel Semjonow; Hans Lilja; Caroline Savage; Andrew J Vickers; Anders Bjartell
Journal:  Acta Oncol       Date:  2011-06       Impact factor: 4.089

3.  Ultrasound-guided three-dimensional needle steering in biological tissue with curved surfaces.

Authors:  Momen Abayazid; Pedro Moreira; Navid Shahriari; Sachin Patil; Ron Alterovitz; Sarthak Misra
Journal:  Med Eng Phys       Date:  2014-10-31       Impact factor: 2.242

4.  MRI-guided prostate motion tracking by means of multislice-to-volume registration.

Authors:  Hadi Tadayyon; Siddharth Vikal; Sean Gill; Andras Lasso; Gabor Fichtinger
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2010

5.  Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?

Authors:  Yuanyuan Liang; Norma S Ketchum; Phyllis J Goodman; Eric A Klein; Ian M Thompson
Journal:  J Urol       Date:  2014-04-18       Impact factor: 7.450

6.  High-risk prostate cancer: value of multi-modality 3T MRI-guided biopsies after previous negative biopsies.

Authors:  Jurgen J Fütterer; Sadhna Verma; Thomas Hambrock; Derya Yakar; Jelle O Barentsz
Journal:  Abdom Imaging       Date:  2012-10

Review 7.  Molecular diagnosis of prostate cancer.

Authors:  Eduardo I Canto; Shahrokh F Shariat; Kevin M Slawin
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.